07X.F ANNOVIS BIO INC. DL-0001

Healthcare Biotechnology Frankfurt Exchange
0.7670 EUR
Close of Nov 11, 2026
0.5950 4.61
Market cap
EUR 33.0M
P/E
-
P/B
24.00x
ROE
-
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.

Is 07X.F undervalued?

Graham number

The Graham number of ANNOVIS BIO INC. DL-0001 cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

ANNOVIS BIO INC. DL-0001 fundamental analysis

No fundamental analysis for ANNOVIS BIO INC. DL-0001 yet.

ANNOVIS BIO INC. DL-0001 stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About ANNOVIS BIO INC. DL-0001

Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration in the United States. The company's lead product candidate is Buntanetap, which is in phase 3 to treat alzheimer's disease, as well as in open-label phase 3 to treat parkinson's disease. It also develops ANVS405, which is in phase 2 and 3 clinical trials for the treatment of traumatic brain injury and/or stroke; and ANVS301, which finished phase 1 clinical trial developed to …

Full company profile